27 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast PeerView Press

    • Science

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Stephen Krieger, MD, FAAN / Clyde E. Markowitz, MD - Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers

    Stephen Krieger, MD, FAAN / Clyde E. Markowitz, MD - Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers

    Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms of MS, Assess available data on the potential prognostic and predictive utility of serum neurofilament light chain levels in patients with MS, Develop strategies based on clinical phenotypes, goals, preferences, and potential biomarker findings when selecting disease-modifying therapies for patients with MS.

    • 51 min
    "Brenda L. Banwell, MD, FAAP, FRCPC, FAAN - Addressing Barriers to the Ready Recognition and Timely Treatment of Pediatric Multiple Sclerosis"

    "Brenda L. Banwell, MD, FAAP, FRCPC, FAAN - Addressing Barriers to the Ready Recognition and Timely Treatment of Pediatric Multiple Sclerosis"

    Go online to PeerView.com/DKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multiple sclerosis expert discusses diagnosing, treating, and managing pediatric-onset multiple sclerosis. Upon completion of this activity, participants should be better able to: Identify patients with pediatric-onset multiple sclerosis according to their presenting symptoms and established criteria, Assess available data on approved disease-modifying therapies for the treatment of pediatric-onset multiple sclerosis, Select an appropriate course of disease-modifying therapy in individuals with pediatric- onset multiple sclerosis

    • 32 min
    Diana Castro, MD - Altering the Natural History of Spinal Muscular Atrophy: A Compelling Story Highlighting the Critical Role of Presymptomatic Treatment

    Diana Castro, MD - Altering the Natural History of Spinal Muscular Atrophy: A Compelling Story Highlighting the Critical Role of Presymptomatic Treatment

    Go online to PeerView.com/SDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric neurology uses a novel, interactive talk to guide learners through the diagnosis and presymptomatic treatment of spinal muscular atrophy (SMA). Upon completion of this activity, participants should be better able to: Identify the important role of newborn screening in the presymptomatic treatment of spinal muscular atrophy, Cite available data on approved therapies for the treatment of spinal muscular atrophy, including presymptomatic patients, Apply approved therapies in presymptomatic patients with spinal muscular atrophy

    • 25 min
    Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    Go online to PeerView.com/UYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses new and late-breaking data on current and emerging treatments for multiple sclerosis from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). Upon completion of this activity, participants should be better able to: Employ recently presented data related to approved disease-modifying therapies when treating patients with multiple sclerosis, Examine new data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Recognize the potential clinical utility of investigational disease-modifying therapies in the future management of multiple sclerosis

    • 11 min
    Steven Brem, MD - Brainstorming Personalized Care Strategies in Glioblastoma: Rethinking and Refining Therapeutic Algorithms With Tumor Treating Fields and Novel Systemic Approaches

    Steven Brem, MD - Brainstorming Personalized Care Strategies in Glioblastoma: Rethinking and Refining Therapeutic Algorithms With Tumor Treating Fields and Novel Systemic Approaches

    Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials

    • 54 min
    Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Across a Range of Solid Malignancies

    Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Across a Range of Solid Malignancies

    Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials

    • 1 hr 19 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press